Browsing by Author "Lopez, Giselle Y"

Now showing items 1-5 of 5

    • Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 

      Jin, Genglin; Reitman, Zachary J; Duncan, Christopher G; Spasojevic, Ivan; Gooden, David M; Rasheed, B Ahmed; Yang, Rui; ... (12 authors) (Cancer research, 2013-01)
      Point mutations at Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the "oncometabolite" D-2-hydroxyglutarate (D-2HG). ...

    • EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. 

      Feng, Haizhong; Lopez, Giselle Y; Kim, Chung Kwon; Alvarez, Angel; Duncan, Christopher G; Nishikawa, Ryo; Nagane, Motoo; ... (27 authors) (The Journal of clinical investigation, 2014-09)
      Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens ...

    • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 

      Lopez, Giselle Y; Reitman, Zachary J; Solomon, David; Waldman, Todd; Bigner, Darell D; McLendon, Roger E; Rosenberg, Steven A; ... (9 authors) (Biochemical and biophysical research communications, 2010-07-13)
      Isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are enzymes which convert isocitrate to alpha-ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+to NADPH). IDH1/2 were ...

    • Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. 

      Guo, Changcun; Pirozzi, Christopher J; Lopez, Giselle Y; Yan, Hai (Current opinion in neurology, 2011-12)
      Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native ...

    • Mutant IDH1 is required for IDH1 mutated tumor cell growth. 

      Jin, Genglin; Pirozzi, Christopher J; Chen, Lee H; Lopez, Giselle Y; Duncan, Christopher G; Feng, Jie; Spasojevic, Ivan; ... (10 authors) (Oncotarget, 2012-08)
      Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. ...